Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (“Jiuyuan Gene”) has issued the proxy form for its Annual General Meeting scheduled for 14:00 on 15 June 2026 at Conference Room 3, No. 23 Eighth Street, Baiyang Street, Qiantang District, Hangzhou.

Key items to be voted on:

1. 2025 Operating Reports • Board, Independent Non-executive Directors and Supervisory Committee reports for 2025. • Audited consolidated financial statements and independent auditor’s report for 2025. • Annual Report and ESG Report for 2025.

2. Profit Distribution • A 2025 profit distribution plan will be submitted for shareholder approval. Specific figures were not disclosed in the proxy document.

3. Auditor Re-appointment • Ernst & Young and Ernst & Young Hua Ming LLP are nominated as external auditors for 2026, with the Board authorised to set remuneration.

4. Board and Remuneration Matters • Director remuneration for 2026. • Appointment of a new independent non-executive director (name not specified in the proxy).

5. Corporate Governance Amendments • Proposed changes to the Rules of Procedures for the Board of Directors and the Shareholders’ General Meeting. • Proposal to abolish the Supervisory Committee, accompanied by corresponding amendments to the Articles of Association.

6. Business Scope and Capital Authorities • Special resolution to adjust the company’s business scope. • General mandates for new share issuance and share repurchase.

Voting thresholds: Ordinary resolutions require ≥50 % of votes cast; special resolutions require ≥66.67 %.

Shareholders of both unlisted shares and H shares may appoint proxies. Forms must reach Computershare Hong Kong Investor Services Limited by 14:00 on 14 June 2026 (Hong Kong time). Attendance in person is still permitted even after submitting a proxy, in which case the proxy is deemed revoked.